Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II

• Published in: European journal of clinical pharmacology Vol. 39; no. 2; pp. 101 - 105
• Main Authors: SAXENHOFER, H, WEIDMANN, P, RIESEN, W. F, BERETTA-PICCOLI, C, FRAGIACOMO, C, WUNDERLIN, R, NOSEDA, G
• Format: Journal Article
• Language: English
• Published: Heidelberg Springer 01-08-1990; Berlin
• Subjects: Anticholesteremic Agents - therapeutic use; Apolipoproteins B - blood; Apolipoproteins E - blood; Apoproteins - blood; Biological and medical sciences; Cholesterol, LDL - blood; Double-Blind Method; Female; General and cellular metabolism. Vitamins; Heptanoic Acids - therapeutic use; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II - drug therapy; Lipids - blood; Male; Medical sciences; Middle Aged; Naphthalenes - therapeutic use; Pharmacology. Drug treatments; Pravastatin; Triglycerides - blood; Therapeutic efficiency; Human; Enzyme inhibitor; Controlled therapeutic trial; Lipids; Hyperlipoproteinemia; Apolipoproteins; Cholesterol; Chemotherapy; Metabolic disorder; Hydroxymethylglutaryl-CoA reductase; Chemical test; Antilipemic agent
• ISSN: 0031-6970; 1432-1041
• DOI: 10.1007/bf00280040

The efficacy and safety of the HMG-CoA-reductase inhibitor pravastatin was assessed in a double-blind, placebo controlled study. Thirty patients (51 y) with hyperlipoproteinaemia Type IIa (N = 22) or IIb (N = 8) received for 16 weeks either pravastatin 5 mg b.d. for 8 weeks followed by 10 mg b.d. for 8 weeks (Group I), or 10 mg b.d. for 8 weeks followed by 20 mg b.d. to 16 weeks (Group II), or placebo (Group III). In Groups I and II, mean serum total cholesterol was reduced by -26% and -22%, respectively; low-density lipoprotein (LDL)-cholesterol decreased by -28% and -27%, apolipoprotein B by -25% and -23%, and apolipoprotein E by -9% (NS) and -16%, respectively. Serum high-density lipoprotein (HDL)-cholesterol was increased by 11% in Group II, and so the total/HDL-cholesterol ratio fell by 33%. Apoprotein A1 and A2 were not significantly changed. No serious clinical and laboratory abnormalities were observed. The data suggest considerable therapeutic efficacy of pravastatin in the treatment of Type II hyperlipoproteinaemia.